 "Suven Life Sciences surges on securing patents for neurodegenerative drug")
Suven Life Sciences has surged 6% to Rs 220 on BSE after the pharmaceuticals company said it has been granted product patents by Australia, Hong Kong and Japan, for drug used in the treatment of neurodegenerative diseases.
“The company has secured one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2030,” Suven Life Sciences said in a BSE filing.
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong, it added.
The stock opened at Rs 211 and hit a high of Rs 226 on BSE. Till 1042 hours, a combined 1.43 million shares changed hands against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
“The company has secured one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2030,” Suven Life Sciences said in a BSE filing.
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong, it added.
The stock opened at Rs 211 and hit a high of Rs 226 on BSE. Till 1042 hours, a combined 1.43 million shares changed hands against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%